PITTSBURGH, PA – Carmell Corporation, a medical device company based in Pittsburgh, Pennsylvania, convened its 2024 Annual Meeting of Stockholders on July 12, where key decisions regarding its board and accounting firm were made. The meeting saw the election of a director and the ratification of the company's independent registered public accounting firm for the upcoming fiscal year.
During the Annual Meeting, stockholders elected Richard Upton as a Class I director to serve on Carmell Corp's Board of Directors. Upton will serve a three-year term ending in 2027. Out of the 11,471,693 shares represented at the meeting, 9,525,320 votes were cast in favor of Upton, with 24,465 withholdings. Additionally, there were 1,921,908 broker non-votes.
The second proposal was the ratification of Adeptus Partners, LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2024. This proposal passed with 11,455,591 votes for, 12,663 against, and 3,439 abstentions.
The quorum for the meeting was achieved with 56% of the outstanding shares as of May 31, 2024, present or represented by proxy. The company, which is categorized under the Surgical & Medical Instruments & Apparatus industry, has its common stock and warrants listed on The Nasdaq Stock Market under the symbols CTCX and CTCXW, respectively.
Carmell Corp, previously known as Carmell Therapeutics Corp and ALPHA HEALTHCARE ACQUISITION CORP III, has undergone name changes in recent years, with the latest occurring on July 27, 2023. The company is incorporated in the state of Delaware and has its fiscal year end on December 31.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.